AstraZeneca leadership at a press conference

Latest press releases

Thursday, 18 September 2014
AstraZeneca named among “100 Best Companies for Working Mothers” For the 13th consecutive year, AstraZeneca has been selected by Working Mother magazine as one of its Working Mother 100 Best Companies. This annual listing recognizes 100 companies for their outstanding leadership in establishing policies, programs and corporate cultures that support working moms, including through child care services, flexible work arrangements, paid parental leave and advancement opportunities for women.
Tuesday, 16 September 2014
FDA approves MOVANTIK™ (naloxegol) Tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK™ (naloxegol) Tablets C-II as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.
Monday, 15 September 2014
Actor James Van Der Beek and AstraZeneca join forces to educate families about influenza The makers of FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) and the “CSI: Cyber” star launch national campaign to dispel common misconceptions about flu and annual vaccination.
Monday, 8 September 2014
BYDUREON® Pen, a treatment option for adults with type 2 diabetes, now available in pharmacies AstraZeneca today announced that once-weekly BYDUREON® (exenatide extended-release for injectable suspension) Pen 2 mg, a prescription medicine, is now available in pharmacies across the United States. BYDUREON is approved by the U.S. Food and Drug Administration as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Tuesday, 19 August 2014
US Department of Justice closes investigation into PLATO clinical trial for BRILINTA AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with BRILINTA® (ticagrelor) tablets. The government is not planning any further action.
Thursday, 31 July 2014
AstraZeneca PLC second quarter and half year results 2014 Visit our global site to view full details of the event.
Thursday, 26 June 2014
CDC Advisory Committee recommends preferential use of Live Attenuated Influenza Vaccine (LAIV) for eligible children 2 to 8 years of age The MedImmune Specialty Care division of AstraZeneca announced that the U.S. Centers for Disease Control & Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) recommended that when available, Live Attenuated Influenza Vaccine (LAIV) should be used for healthy children 2 to 8 years of age, who have no contraindications or precautions.
Tuesday, 3 June 2014
New study reveals significant burden of RSV disease among U.S. preterm infants born at 32-35 weeks The MedImmune Specialty Care division of AstraZeneca (MedImmune Specialty Care) announced today the publication of results from a new study that examined the burden of Respiratory Syncytial Virus (RSV) in preterm infants not receiving RSV immunoprophylaxis.
Monday, 2 June 2014
Cigna customers prescribed CRESTOR may lower their bad cholesterol with reduced out-of-pocket costs Cigna has entered into a first-of-its-kind contract with AstraZeneca to help ensure that customers are given an appropriate cholesterol-lowering medication based on their treatment need.
Tuesday, 6 May 2014
FDA approves EPANOVA for the treatment of adults with severe hypertriglyceridemia AstraZeneca today announced the US Food and Drug Administration (FDA) approved EPANOVA® (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL).

Please note

These press releases were issued in the United States (US) and are posted here as reference information for US investors and journalists only. The information contained in each press release was accurate at the time of issuance, and AstraZeneca assumes no responsibility for updating the information to reflect subsequent developments.

View information on AstraZeneca products, including their current US Prescribing Information.